Sanofi inks COVID-19 mRNA vaccine deal with Translate BioDaiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain

A phase 3 study from Daiichi Sankyo Company conducted in Japan, South Korea and Taiwan found that mirogabalin, an orally administered gabapentinoid, was associated with a significantly greater improvement in pain among patients with central neuropathic pain after spinal cord injury compared with placebo.